{"id":"https://openalex.org/W4361964778","doi":"https://doi.org/10.1158/1078-0432.c.6532511","title":"Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer","display_name":"Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361964778","doi":"https://doi.org/10.1158/1078-0432.c.6532511"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6532511","doi":"https://doi.org/10.1158/1078-0432.c.6532511","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6532511","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.6532511","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049097819","display_name":"Milan M. Radovich","orcid":"https://orcid.org/0000-0001-9667-156X","observed_orcids":["https://orcid.org/0000-0001-9667-156X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Milan Radovich","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9667-156X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049263574","display_name":"Jeffrey P. Solzak","orcid":"https://orcid.org/0000-0001-9099-9257","observed_orcids":["https://orcid.org/0000-0001-9099-9257"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey P. Solzak","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9099-9257","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076252332","display_name":"Chao J. Wang","orcid":"https://orcid.org/0000-0001-8951-5657","observed_orcids":["https://orcid.org/0000-0001-8951-5657"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chao J. Wang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8951-5657","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112223190","display_name":"Bradley Allen Hancock","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bradley A. Hancock","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006346528","display_name":"Sunil Badve","orcid":"https://orcid.org/0000-0001-8861-9980","observed_orcids":["https://orcid.org/0000-0001-8861-9980"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sunil Badve","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8861-9980","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080410100","display_name":"Sandra K. Althouse","orcid":"https://orcid.org/0000-0001-6970-2332","observed_orcids":["https://orcid.org/0000-0001-6970-2332"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sandra K. Althouse","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066378604","display_name":"Steven M. Bray","orcid":"https://orcid.org/0000-0002-0854-8121","observed_orcids":["https://orcid.org/0000-0002-0854-8121"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Steven M. Bray","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0854-8121","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053390874","display_name":"Anna Maria Storniolo","orcid":"https://orcid.org/0000-0002-8701-7889","observed_orcids":["https://orcid.org/0000-0002-8701-7889"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna Maria V. Storniolo","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8701-7889","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064891388","display_name":"Tarah Jean Ballinger","orcid":"https://orcid.org/0000-0002-6797-2758","observed_orcids":["https://orcid.org/0000-0002-6797-2758"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tarah J. Ballinger","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6797-2758","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009816526","display_name":"Bryan Paul Schneider","orcid":"https://orcid.org/0000-0003-1868-7739","observed_orcids":["https://orcid.org/0000-0003-1868-7739"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bryan P. Schneider","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1868-7739","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5068666503","display_name":"Kathy D. Miller","orcid":"https://orcid.org/0000-0002-7125-883X","observed_orcids":["https://orcid.org/0000-0002-7125-883X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kathy D. Miller","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7125-883X","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9169999957084656,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9169999957084656,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.03669999912381172,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.03660000115633011,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gedatolisib","display_name":"gedatolisib","score":0.9710000157356262},{"id":"https://openalex.org/keywords/metastatic-triple-negative-breast-cancer","display_name":"metastatic triple-negative breast cancer","score":0.9350000023841858},{"id":"https://openalex.org/keywords/pi3k-inhibition","display_name":"PI3K inhibition","score":0.8600000143051147},{"id":"https://openalex.org/keywords/wnt-signaling","display_name":"Wnt signaling","score":0.847000002861023},{"id":"https://openalex.org/keywords/ptk7","display_name":"PTK7","score":0.9760000109672546},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.8299999833106995},{"id":"https://openalex.org/keywords/pi3k-mtor-inhibitors","display_name":"PI3K/mTOR inhibitors","score":0.8240000009536743},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7409999966621399},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.48399999737739563},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.6919999718666077},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9620000123977661},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.7070000171661377},{"id":"https://openalex.org/keywords/genetic-alterations","display_name":"genetic alterations","score":0.39100000262260437}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7008336186408997},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6672658324241638},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.6012232303619385},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5284096002578735},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4065704345703125},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.39647406339645386}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.6532511","doi":"https://doi.org/10.1158/1078-0432.c.6532511","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6532511","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6532511","doi":"https://doi.org/10.1158/1078-0432.c.6532511","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6532511","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8100000023841858}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1966181922","https://openalex.org/W2554176272","https://openalex.org/W1999292713","https://openalex.org/W80971072","https://openalex.org/W2366029130","https://openalex.org/W3044626609","https://openalex.org/W3005028195","https://openalex.org/W2376078656","https://openalex.org/W2050936961","https://openalex.org/W2101673433"],"abstract_inverted_index":{"AbstractPurpose:":[0],"The":[1,117,251],"PI3K":[2,18,24,246],"pathway":[3,79],"is":[4,41,275],"dysregulated":[5],"in":[6,22,47,50,149,244,272],"the":[7,33,74,245],"majority":[8],"of":[9,17,32,38,144,253,268],"triple-negative":[10],"breast":[11,104],"cancers":[12],"(TNBC),":[13],"yet":[14],"single-agent":[15],"inhibition":[16,25],"has":[19],"been":[20],"ineffective":[21],"TNBC.":[23],"leads":[26],"to":[27],"an":[28,70,82],"immediate":[29],"compensatory":[30],"upregulation":[31],"Wnt":[34],"pathway.":[35],"Dual":[36],"targeting":[37],"both":[39],"pathways":[40],"highly":[42],"synergistic":[43],"against":[44,73],"TNBC":[45,92,274],"models":[46],"vitro":[48],"and":[49,67,86,99,106,138,176,188,247,261],"vivo.":[51],"We":[52],"initiated":[53],"a":[54,61],"phase":[55],"I":[56,63],"clinical":[57,129,237,264],"trial":[58],"combining":[59],"gedatolisib,":[60],"pan-class":[62],"isoform":[64],"PI3K/mTOR":[65],"inhibitor,":[66],"cofetuzumab":[68,158,256],"pelidotin,":[69],"antibody\u2013drug":[71],"conjugate":[72],"cell-surface":[75],"PTK7":[76,248],"protein":[77],"(Wnt":[78],"coreceptor)":[80],"with":[81,236,241],"auristatin":[83],"payload.":[84],"Patients":[85],"Methods:":[87],"Participants":[88],"(pt)":[89],"had":[90,107,209,215],"metastatic":[91,273],"or":[93],"estrogen":[94],"receptor":[95],"(ER)":[96],"low":[97],"(ER":[98],"PgR":[100],"<":[101],"5%,":[102],"HER2-negative)":[103],"cancer,":[105],"received":[108],"at":[109,131],"least":[110],"one":[111],"prior":[112],"chemotherapy":[113],"for":[114,218,232],"advanced":[115],"disease.":[116],"primary":[118],"objective":[119],"was":[120,199,202,222,226,258],"safety.":[121],"Secondary":[122],"endpoints":[123],"included":[124],"overall":[125],"response":[126],"rate":[127],"(ORR),":[128],"benefit":[130,238],"18":[132,145],"weeks":[133,164],"(CB18),":[134],"progression-free":[135],"survival":[136],"(PFS),":[137],"correlative":[139],"analyses.":[140],"Results:":[141],"A":[142],"total":[143],"pts":[146,208],"were":[147,190,239],"enrolled":[148],"three":[150],"dose":[151],"cohorts:":[152],"gedatolisib":[153,254],"110":[154],"mg":[155,169,178],"weekly":[156],"+":[157,170,179,255],"pelidotin":[159,257],"1.4":[160,171],"mg/kg":[161,172,181],"every":[162],"3":[163,196,207],"(n":[165,173,182],"=":[166,174,183],"4),":[167],"180":[168,177],"3),":[175],"2.8":[180],"11).":[184],"Nausea,":[185],"anorexia,":[186],"fatigue,":[187],"mucositis":[189],"common":[191],"but":[192],"rarely":[193],"reached":[194],"\u2265grade":[195],"severity.":[197],"Myelosuppression":[198],"uncommon.":[200],"ORR":[201],"16.7%":[203],"(3/18).":[204],"An":[205],"additional":[206],"stable":[210,216],"disease":[211,217],"(of":[212],"these":[213],"2":[214],">18":[219],"weeks);":[220],"CB18":[221],"27.8%.":[223],"Median":[224],"PFS":[225],"2.0":[227],"months":[228],"(95%":[229],"confidence":[230],"interval":[231],"PFS:":[233],"1.2\u20136.2).":[234],"Pts":[235],"enriched":[240],"genomic":[242],"alterations":[243],"pathways.":[249],"Conclusions:":[250],"combination":[252,271],"well":[259],"tolerated":[260],"demonstrated":[262],"promising":[263],"activity.":[265],"Further":[266],"investigation":[267],"this":[269],"drug":[270],"warranted.":[276]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2025-10-10T00:00:00"}